Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05513053 · ClinicalTrials.gov registry record · Phase 3
Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.
A Phase 3 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,308
- Enrollment target
NCT05513053 is a Phase 3 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 1,308 participants.
The verdict
NCT05513053, a Phase 3 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,308 participants
- Enrollment target
Study Summary
The purpose of this study was to demonstrate the non-inferiority (NI) of the HAI immune response of RIV4 in participants aged 9 to 17 years vs participants aged 18 to 49 years and to describe the immunogenicity and safety profile of RIV4 in all participants.
Interventions
- BIOLOGICAL Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,308 participants |
| Start Date | 2022-10-27 |
| Est. Completion | 2023-10-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05513053
The ClinicalTrials.gov registry entry for NCT05513053 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,308 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH is the first listed.
NCT05513053 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05513053 about?
NCT05513053 is a clinical study titled "Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.". The purpose of this study was to demonstrate the non-inferiority (NI) of the HAI immune response of RIV4 in participants aged 9 to 17 years vs participants aged 18 to 49 years and to describe the immunogenicity and safety profile of RIV4 in all participants.
What is the current status of trial NCT05513053?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,308 participants. The study started on 2022-10-27. Estimated completion is 2023-10-27.
What interventions are being tested in trial NCT05513053?
The interventions under investigation include: Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH (BIOLOGICAL).
Who is sponsoring clinical trial NCT05513053?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.